Chemed Corporation (CHE)
NYSE: CHE
· Real-Time Price · USD
572.07
-0.94 (-0.16%)
At close: May 29, 2025, 3:59 PM
573.19
0.20%
After-hours: May 29, 2025, 04:07 PM EDT
Chemed Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| All Other Revenue Self Pay Respite Care Ect. Revenue | 19.45M | 13.58M | 12.44M | 12.14M | 11.16M | 10.43M | 7.83M |
| All Other Revenue Self Pay Respite Care Ect. Revenue Growth | +43.24% | +9.20% | +2.44% | +8.76% | +7.01% | +33.23% | n/a |
| Care Services Total Revenue | 1.55B | 1.33B | n/a | n/a | n/a | n/a | n/a |
| Care Services Total Revenue Growth | +15.91% | n/a | n/a | n/a | n/a | n/a | n/a |
| Continuous Care Revenue | 99.75M | 85.67M | n/a | n/a | n/a | n/a | n/a |
| Continuous Care Revenue Growth | +16.43% | n/a | n/a | n/a | n/a | n/a | n/a |
| Inpatient Care Revenue | 120.6M | 112.42M | n/a | n/a | n/a | n/a | n/a |
| Inpatient Care Revenue Growth | +7.28% | n/a | n/a | n/a | n/a | n/a | n/a |
| Routine Home Care Revenue | 1.33B | 1.14B | n/a | n/a | n/a | n/a | n/a |
| Routine Home Care Revenue Growth | +16.72% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 105.59M | 104.25M | 101.98M | 102.25M | 115.87M | 100.44M | 95.34M | 94.99M | 97.58M | 96.93M | 83.99M | 87.85M | 93.89M | 92.07M | 89.22M | 93.84M | 91.6M | 86.81M | 88.32M | 84.51M | 70.58M | 83.29M | 76.84M | 71.56M | 74.03M | 65.73M | 67.18M | 68.3M | 69M | 71.62M | 66.92M | 68.65M | 69.46M | 62.53M | 59.37M | 62.63M | 59.05M | 64.55M | 55.2M | 57.99M | 58.59M |
| Selling, General, and Administrative Revenue Growth | +1.28% | +2.23% | -0.27% | -11.75% | +15.37% | +5.34% | +0.38% | -2.66% | +0.67% | +15.40% | -4.39% | -6.43% | +1.97% | +3.20% | -4.92% | +2.44% | +5.52% | -1.71% | +4.50% | +19.74% | -15.26% | +8.40% | +7.38% | -3.34% | +12.62% | -2.15% | -1.64% | -1.02% | -3.66% | +7.03% | -2.53% | -1.16% | +11.09% | +5.31% | -5.20% | +6.07% | -8.53% | +16.95% | -4.82% | -1.01% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |